Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

The identification of epidermal growth factor receptor (EGFR) mutations represented a fundamental step forward in the treatment of advanced non-small cell lung cancer (NSCLC) as they define a subset of patients who benefit from the administration of specifically designed targeted therapies. The inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Baglivo, Sara, Paglialunga, Luca, De Giglio, Andrea, Bellezza, Guido, Chiari, Rita, Crinò, Lucio, Metro, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455880/
https://www.ncbi.nlm.nih.gov/pubmed/28607578
http://dx.doi.org/10.1177/1758834017702820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455880/
https://www.ncbi.nlm.nih.gov/pubmed/28607578
http://dx.doi.org/10.1177/1758834017702820

Ejemplares similares